Abstract
GBA1 variants and decreased glucocerebrosidase (GCase) activity are implicated in Parkinson’s disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), one of GCase main substrates, are involved in PD pathogenesis. Using multiple genetic methods, we show that ATP10D, not GBA1, is the main regulator of plasma GlcCer levels, yet it is not involved in PD pathogenesis. Plasma GlcCer levels were associated with PD, but not in a causative manner, and are not predictive of disease status. These results argue against targeting GlcCer in GBA1-PD and underscore the need to explore alternative mechanisms and biomarkers for PD.
Competing Interest Statement
A.J., C.B., R.S., G.B., K.K.K., M.I.I., and P.B are current or previous employees of CENTOGENE GmbH, which is investigating the role of GlcCer in PD for investigational therapy development. H.I. and M.T.'s participation in this project was part of a competitive contract awarded to Data Tecnica LLC by the National Institutes of Health to support open science research.
Funding Statement
This study was financially supported through grants from the Michael J. Fox Foundation (MJFF). This work was supported in part by the Intramural Research Program of the National Institute on Aging (NIA), and the Center for Alzheimer's and Related Dementias (CARD), within the Intramural Research Program of the National Institute on Aging and the National Institute of Neurological Disorders and Stroke (1ZIA-AG000546).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB of McGill University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code for analyses used in this project can be found at https://github.com/gan-orlab/GlcCer_GWAS/. PPMI data used in the present study can be accessed by qualified researchers through completion of a data access application (https://www.ppmi-info.org/access-data-specimens/download-data). Data from the Centogene cohort may be made available on request due to restrictions. All PPMI plasma GlcCer GWAS summary statistics are publicly available in the GWAS catalog (https://www.ebi.ac.uk/gwas/home).
